WO2013168006A2 - Compositions et méthodes de traitement de la douleur locale - Google Patents

Compositions et méthodes de traitement de la douleur locale Download PDF

Info

Publication number
WO2013168006A2
WO2013168006A2 PCT/IB2013/051268 IB2013051268W WO2013168006A2 WO 2013168006 A2 WO2013168006 A2 WO 2013168006A2 IB 2013051268 W IB2013051268 W IB 2013051268W WO 2013168006 A2 WO2013168006 A2 WO 2013168006A2
Authority
WO
WIPO (PCT)
Prior art keywords
pain
compositions
pharmaceutical composition
administration
formula
Prior art date
Application number
PCT/IB2013/051268
Other languages
English (en)
Other versions
WO2013168006A3 (fr
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Priority to EP13788349.2A priority Critical patent/EP2882745A2/fr
Priority to CA2873138A priority patent/CA2873138A1/fr
Priority to SG11201407323WA priority patent/SG11201407323WA/en
Priority to AU2013257727A priority patent/AU2013257727B2/en
Priority to CN201380030659.5A priority patent/CN105612155A/zh
Priority to JP2015510898A priority patent/JP2016508956A/ja
Publication of WO2013168006A2 publication Critical patent/WO2013168006A2/fr
Priority to ZA2014/08055A priority patent/ZA201408055B/en
Publication of WO2013168006A3 publication Critical patent/WO2013168006A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This disclosure generally relates to compounds and compositions for the treatment of local pain. More particularly, this invention relates to treating subjects with a pharmaceutically acceptable dose of compounds, crystals, polymorphs, esters, salts, stereoisomers, enantiomers, hydrates, prodrugs, or mixtures thereof.
  • ain is a subjective experience, influenced by physical, psychological, social, and spiritual factors. The concept of total pain acknowledges the importance of all these dimensions and that good pain relief is unlikely without attention to each aspect. Pain and diseases such as cancer are n t synonymous: at least two tinrds of patients experience pain at some time during the course of their illness, and most will need potent analgesics.
  • Severe Pain such as pain, depression, fibromyalgia, rheumatoid arthritis, restless leg syndrome, bipolar disorder are a heterogeneous group of diseases of the nervous system, including the brain, spinal cord, and peripheral nerves that have much different aetiology. Many are hereditary; some are secondary to toxic or metabolic processes. Free radicals are highly reactive molecules or chemical species capable of independent existence. Generation of highly Reactive Oxygen Species ( OS) is an integral feature of normal cellular function like mitochondrial respiratory chain, phagocytosis and arachido.rs.ic acid meiaboiism. The release of oxygen free radicals has also been reported during the recovery phases from many pathological noxious stimuli to the cerebral tissues.
  • OS highly Reactive Oxygen Species
  • Some of the pain associated neurological disorders include injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.
  • the present invention provides compounds, compositions containing these compounds and methods for using the same to treat, prevent and/or ameliorate the effects of the conditions such as local pai .
  • compositions comprising of formula I or pharmaceutical acceptable salts, hydrate, solvate, prodrug, enantiomer, or stereoisomer thereof.
  • the invention also provides pharmaceutical compositions comprising one or more compounds of formula 1 or intermediates thereof and one or more of pharmaceutically acceptable carriers, vehicles or diluents. These compositions may be used in the treatment of local pain and its associated complications.
  • the present invention relates io the compounds and compositions of formula ⁇ , or pharmaceutically acceptable salts, hydrate, solvate, prodrug, enanttomer or stereoisomer thereof.
  • R independently represents D, -C3 ⁇ 4 -OC3 ⁇ 4, ,
  • a is independently 2,3 or 7.
  • each b is independently 3, 5 or 6;
  • e is independently 1 , 2 or 6;
  • c and d are each independently H, D, -OH, -OD, Ci -Co-alky i, - 3 ⁇ 4 or -COC3 ⁇ 4; n is independently 1 , 2, 3, 4 or 5,
  • kits comprising any of the pharmaceutical compositions disclosed herein.
  • the kit may comprise instructions for use in the treatment of local pain or its related complications.
  • the application also discloses a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceiiticaliy acceptable carrier and any of the compositions herein.
  • the pharmaceutical com position is formulated for systemic administration, oral administration, sustained release, parenteral administration, injection, subdermal administration, or transdermal administration.
  • kits comprising the pharmaceutical compositions described herein.
  • the kits may further comprise instructions for use in the treatment of local pain or its related complications.
  • compositions described herein have several uses.
  • the present application provides, for example, methods of treating a patient suffering from local pain or its related complications manifested from metabolic conditions, severe diseases or disorders; Hepatol ogy. Cancer, Hematol gical, Orthopedic, Cardiovascular, Renal, Skin, Neurological or Ocular com plications. DETAILED DESCRIPTION OF TH E INVENTION
  • the compounds of the present invention can be present in the form of pharmaceutically acceptable salts.
  • the compounds of the present invention can also be present in the form of pharmaceutically acceptable esters (i .e., the methyl and ethyl esters of the acids of formula 1 to be used as prodrugs).
  • the compounds of the present invention can also be solvated, i.e. hydrated. The solvation can be affected in the course of the manufacturing process or can take place i.e. as a consequence of hygroscopic properties of an initially anhydrous compound of formula £ (hydration).
  • isomers Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement, of their atoms in space are termed “stereoisomers.” Diastereomers are stereoisomers with opposite configuration at one or more chiral centers which are not enantiomers. Stereoisomers bearing one or more asymmetric centers that are non ⁇ superimposable mirror linages of each oilier are termed “enantiomers.” When a. compound has an asymmetric center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center or centers and is described by the R- and S-sequencing rales of Cahn, lngold and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+ ⁇ or (-)-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof.
  • racemic mixture A mixture containing equal proportions of the enantiomers is called a "racemic mixture”
  • the term “metabolic condition” refers to an inborn errors of metabolism (or genetic metabolic conditions) are genetic disorders that result from a defect in one or more metabolic pathways; specifically, the function of an enzyme is affected and is either deficient or completely absent.
  • a molecular conjugate comprises of compounds selected from, the group consisting of R-lipoic acid (CAS No. 1200-22-2), salsalate (CAS No. 552-94-3), acetylcysteine (CAS No. 616-91 -1), Eicosapentaenoic acid (CAS No. 10417- 94-4), Docosahexaenoic acid (CAS No. 6217-54-5).
  • polymorph as used herein is art-recognized and refers to one crystal structure of a given compound.
  • parenteral administration and “administered parenteral! ' as used herein refer to modes of administration other than enteral and topical administration, such as injections, and include without limitation intravenous, intramuscular, intrapleural, intravascular, intraperi cardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradennal, intraperitoneal., transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
  • a "patient,” “subject,” or “host” to be treated by the subject method may mean either a human or non-human animal, such as primates, mammals, and vertebrates.
  • the terra includes compositions, polymers and other materials and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals, human beings and animals without excessive toxicity, irritation, allergic response, or other problem or coiriplicaiion, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable carrier includes, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, solvent or encapsulating material involved in carrying or transporting any subject composition, from one organ, or portion of the body, to another organ, or portion of the body.
  • a pharmaceutically acceptable carrier is non-pyrogenic.
  • materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl celluiose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) mait; (6) gelatin; (7) talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, com oil and soybean oil; (1.0) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mann.itol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar, (14) buffering agents, such as magnesium hvdroxide and aluminum hvdroxide
  • prodrug is intended to encompass compounds that, under physiological conditions, are converted into the therapeutically active agents of the present invention.
  • a common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule, in other embodiments, the prodrug is converted by an enzymatic activity of the host animal.
  • prophylactic or therapeutic treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
  • the term "predicting" as used herein refers to assessing the probability related diseases patient will suffer from abnormalities or complication and/or terminal platelet aggregation or failure and/or death (i.e.
  • the predictive window is an interval in which the subject will develop one or more of the said complications according to the predicted probability.
  • the predictive window may be the entire remaining lifespan of the subject upon analysis by the method of the present invention.
  • treating includes preventing a disease, disorder or condition from occurring in an animal which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it, inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition.
  • Treating the disease or condition includes ameliorating at least one symptom of the particular disease or condition, even if the underlying pathophysiology is not affected, such as local anesthesia including infiltration, nerve block., epidural, intrathecal anesthesia, pain, severe pain, chronic pain, chemotherapy induced pain, neuropathic pain, post herpetic neuralgia, neuralgia of a subject by administration of an agent even though such agent does not treat the cause of the condition.
  • the term “treating " , “treat” or “treatment” as used herein includes curative, preventative (e.g., prophylactic), adjunct and palliative treatment.
  • the phrase "therapeutically effective amount" is an art-recognized term.
  • the term refers to an amount of a salt or composition disclosed herein that produces some desired effect at a reasonable benefit/risk ratio applicable to any medical treatment. In certain embodiments, the term refers to that amount necessary or sufficient to eliminate or reduce medical symptoms for a period of time.
  • the effective amount may vary depending on such factors as the disease or condition being treated, the particular targeted constructs being administered, the size of the subject or the severity of the disease or condition. One of ordinary skill in the art may empirically determine the effective amount of a particular composition without necessitating undue experimentation.
  • the pharmaceutical compositions described herein are formulated in a. manner such, that said compositions will be delivered to a. patient in a therapeutically effective amount, as part of a prophylactic or therapeutic treatment.
  • the desired amount of the composition to be administered to a patient will depend on absorption, inactivation, and excretion rates of the drug as well as the delivery rate of the salts and compositions from the subject compositions, it is to be noted that dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Typically, dosing will be determined using techniques known to one skilled in the art.
  • the optimal concentrati n and/or quantities or amounts of any particular salt or composition may be adjusted to accommodate variations in the treatment parameters.
  • treatment parameters include the clinical use to which the preparation is put, e.g., the site treated, the type of patient, e.g., human or non-human, adult or child, and the nature of the disease or condition.
  • the dosage of the subject compositions provided herein may be determined by reference to the plasma concentrations of the therapeutic composition or other encapsulated materials. For example, the maximum piasma concentration (Cmax) and the area under the plasma concentration-time curve from time 0 to infinity may be used.
  • sustained release When used with respect to a pharmaceutical composition or other material, the term "sustained release" is art-recognized.
  • a subject composition which releases a substance over time may exhibit sustained release characteristics, in contrast to a bolus type administration in which the entire amount of the substance is made biologically available at one time.
  • one or more of the pharmaceutically acceptable excipients may undergo gradual or delayed degradation (e.g., through hydrolysis) with concomitant release of any material incorporated therein, e.g., an therapeutic and/or biologically active salt and/or composition, for a sustained or extended period (as compared to the release from a bolus).
  • This release may result in prolonged delivery of therapeutically effective amounts of any of the therapeutic agents disclosed herein.
  • systemic admini tration administered systemically
  • peripheral administration and “administered peripherally” are art-recognized, and include the administration of a subject composition, therapeutic or other material at a site remote from the disease being treated.
  • Administration of an agent for the disease being treated, even if the agent is subsequently distributed systemically, may be termed “local” or “topical” or “regional” administration, other than directly into the central nervous system, e.g., by subcutaneous administration, such that it enters the patient's system and, thus, is subject to metabolism and other like processes,
  • the phrase 'therapeutically effective amount is an art-recognized term.
  • the term refers to an amount of a salt or composition disclosed herein that produces some desired effect at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the term refers to that amount necessary or sufficient to eliminate or reduce medical symptoms for a period of time.
  • the effective amount may vary dependin on such factors as the disease or condition being treated, the particular targeted constructs bei ng administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art may empirically determine the effective amount of a particular composition without necessitating undue experimentation.
  • compositions disclosed herein are contemplates prodrugs of the compositions disclosed herein, as well as pharmaceutically acceptable salts of said prodrugs.
  • compositions comprising a pharmaceutically acceptable carrier and the composition of a compound of Formula I may be formulated for systemic or topical or oral administration.
  • the pharmaceutical composition may be also formulated for oral administration, oral solution, injection, subdermal administration, or transdermal administration.
  • the pharmaceutical composition may further comprise at least one of a pharmaceutically acceptable stabilizer, diluent, surfactant, filler., binder, and lubricant.
  • the pharmaceutical compositions described herein will incorporate the disclosed compounds and compositions (Formula 1) to be delivered in an amount sufficient to deliver to a patient a therapeutically effective amount of a compound of formula I or composition as part of a prophylactic or therapeutic treatment.
  • the desired concentration of formula I or its pharmaceutical acceptable salts will depend on absorption, inaetivation, and excretion rates of the drug as well as the delivery rate of the salts and compositions from the subject compositions. It is to be noted that dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Typically, dosing will be determined using techniques known to one skilled in the art.
  • the optimal concentration and/or quantities or amounts of any particular compound of formula 1 may be adjusted to accommodate variations in the treatment parameters.
  • treatment parameters include the clinical use to which the preparation is put, e.g., the site treated, the type of patient, e.g., human or non-human, adult or child, and the nature of the disease or condition.
  • concentration and/or amount of any compound of formula ⁇ may be readily identified by routine screening in animals, e.g., rats, by screening a range of concentration and/or amounts of the material in question using appropriate assays.
  • Known methods are also available to assay local tissue concentrations, diffusion rates of the salts or compositions, and local blood flow before and after admini tration of therapeutic formulations disclosed herein.
  • One such method is microdialysis, as reviewed by T. E. Robinson et ah, 1 91 , microdialysis in the neurosciences, Techniques, volume 7, Chapter I .
  • the methods reviewed by Robinson may be applied, in brief, as follows. A microdialysis loop is placed in situ in a test animal.
  • Dialysis fluid is pumped through the loop.
  • compounds with formula I such as those disclosed herein are injected adjacent to the loop, released drugs are collected in the dial sate in proportion to their local tissue concentrations.
  • the progress of diffusion of the salts or compositions may be determined thereby with suitable calibration procedures using known concentrations of salts or compositions.
  • the dosage of the subject compounds of formula I provided herein may be determined by reference to the plasma concentrations of the therapeutic composition or other encapsulated materials. For example, the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve from, time 0 to infinity may be used.
  • Cmax maximum plasma concentration
  • an effective dosage for the compounds of Formulas 1 is in the range of about 0.01 mg/kg/day to about 100 mg/kg/day in single or divided doses, for instance 0.01 mg/kg/day to shout 50 mg/kg/day in single or divided doses.
  • the compounds of Formulas I may be administered at a dose of, for example, less than 0,2 rag/kg/day, 0.5 mg kg day, 1.0 mg/kg/day, 5 mg/kg/day, 10 mg/kg day, 20 mg/kg day, 30 mg kg day, or 40 mg/kg day.
  • Compounds of Formula 1 ma also be administered to a human patient at a dose of for example, between 0.1 nig and 1000 mg, between 5 mg and 80 rag, or less than 1 .0, 9.0, 12.0, 20.0, 50.0, 75.0, 100, 300, 400, 500, 800, 1000, 2000, 5000 mg per day.
  • the compositions herein are administered at an amount that, is less than 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the compound of formula I required for tire same therapeutic benefit.
  • An effective amount of the compounds of formula I described herein refers to the amount of one of said salts or compositions which is capable of inhibiting or preventing a disease
  • An effective amount may be sufficient to prohibit, treat, alleviate, ameliorate, bait, restrain, slow or reverse the progression, or reduce the severity of a complication resulting rom nerve damage or demyelization and/or elevated reactive ox.idaiive- nitrosative species and/or abnormalities in physiological homeostasis' s, in patients who are at risk for such complications.
  • these methods include both medical therapeutic (acute) and/or prophylactic (prevention) administration as appropriate.
  • the amount and timing of compositions administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgment of the prescribing physician.
  • the dosages given above are a guideline and the physician may titrate doses of the drug to achieve the treatment that the physician considers appropriate for the patient.
  • the physician must balance a variety of factors such as age of the patient, presence of preexisting disease, as well as presence of other diseases.
  • compositions provided by this application may be administered to a subject in need of treatment by a variety of conventional routes of administration, snclifding orally, topically, parenteraily, e.g., intravenously, subcutaneo sly or intramedullary. Further, the compositions may be administered intranasally, as a rectal suppository, or using a. "flash" formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water Furthermore, the compositions may be administered to a subject in need of treatment by controlled release dosage forms, site specific drug delivery, transdermal daig delivery, patch (active/passive) mediated drug delivery, by stereotactic injection, or in nanoparticies
  • compositions may be administered alone or in combination with pharmaceutically acceptable carriers, vehicles or diluents, in either single or multiple doses.
  • suitable pharmaceutical carriers, vehicles and diluents include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • the pharmaceutical compositions formed by combining the compositions and the pharmaceutically acceptable carriers, vehicles or diluents are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like.
  • These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
  • tablets containing various excipients such as L-argimne, sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrates such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium siearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Appropriate materials for this include iactose or milk sugar and high molecular weight polyethylene glycols.
  • the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
  • the compounds of formula 1 may also comprise enterically coated comprising of various excipients, as is well known in the pharmaceutical art.
  • solutions of the compositions may be prepared in (for example) sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solutions may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • these particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration, in this connection, the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • the formulations for instance tablets., may contain e g 10 to 100. 50 to 250, 150 to 500 mg, or 350 to 800 mg e.g. 10, 50, 100, 300, 500, 700, S00 mg of the compounds of formula I disclosed herein, for instance, compounds of formula 1 or pharmaceutical acceptable salts of a compounds of Formula L
  • a composition as described herein may be administered orally, or parenterally (e.g., intravenous, intramuscular, subcutaneous or intramedullary).
  • Topical administration may also be indicated, for example, where the patient is suffering from gastrointestinal disorder that prevent oral administration, or whenever the medication is best applied to the surface of a tissue or organ as determined by the attending physician. Localized administration may also be indicated, for example, when a high dose is desired at the target tissue or organ.
  • the active composition may take the form of tablets or lozenges formulated in a conventional manner. [00491
  • the dosage administered will be dependent upon the identity of the metabolic disease; the type of host involved, including its age, health and weight; the kind of concurrent treatment, if any; the frequency of treatment and therapeutic ratio.
  • dosage levels of the administered active ingredients are; intravenous, 0.1 to about 200 mg/kg; intramuscular, 1 to about 500 mg kg; orally, 5 to about 1000 mg kg; intranasal instillation, 5 to about 1000 mg kg; and aerosol, 5 to about 1000 mg/kg of host body weight.
  • an active ingredient can be present in the compositions of the present invention for localized use about the cutis, intranasal ly, pharyngolaryngeally, bronchially, mtravag rally, rectallv, or ocularly in a concentration of from about 0.01 to about 50% w/w of the composition; preferably about 1 to about 20% w/w of the composition, and for parenteral use in a concentration of from about 0.05 to about 50% vv/v of the composition and preferably from about 5 to about 20% w/v.
  • compositions of the present invention are preferably presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders., granules, suppositories, sterile parenteral solutions or suspensions, sterile non-parenterai solutions of suspensions, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient.
  • unit dosage forms such as tablets, capsules, pills, powders., granules, suppositories, sterile parenteral solutions or suspensions, sterile non-parenterai solutions of suspensions, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient.
  • unit dosage forms such as tablets, capsules, pills, powders., granules, suppositories, sterile parenteral solutions or suspensions, sterile non-parenterai solutions of suspensions, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient.
  • solid or fluid unit dosage forms can be prepared.
  • the tablet core contains one or more hydrophilic polymers.
  • Suitable hydrophilic polymers include, but are not limited to, water sweilable cellulose derivatives, polyaJkyiene glycols, thermoplastic polyalkylene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, swelling cross-linked polymers, and mixtures thereof.
  • suitable water sweilable cellulose derivatives include, but are not limited to, sodium carboxy methyl cellulose, cross-linked hydrosypropylcellulose, hydroxy-propyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylceliulose, hy droxybutyl eel iul ose, hydroxyphenylcellulose, hydroxy eth l cellulose (HEC), hydroxypentyleellulose.
  • HPC hydroxy-propyl cellulose
  • HPMC hydroxypropylmethylcellulose
  • HPMC hydroxypropylmethylcellulose
  • hydroxyisopropylceliulose hy droxybutyl eel iul ose
  • hydroxyphenylcellulose hydroxy eth l cellulose
  • HEC hydroxypentyleellulose
  • Suitable poiyalkylene glycols include, but are not limited to, polyethylene glycol.
  • suitable thermoplastic poiyalkylene oxides include, but are not limited to, poly(ethylene oxide).
  • suitable acrylic polymers include, but are not limited to, potassium ethacrySaiedivmylbenzene copolymer, polymethylmethacrylate, high-molecular weight crosslinked acrylic acid homopolymers and copolymers such as those commercially available from Noveon Chemicals under the tradename CA BOPOI, !M .
  • hydrocolloids include, but are not limited to, alginates, agar, guar gum, locust bean gum, kappa carrageenan. iota carrageenan, lara, gum arable, tragacariih, pectin, xanthan gum, gelSan. gum, maltodextrin, galactomannan, pusstulan, laminarin, scJerogiucan, gum arable, inulin., pectin, gelatin, whelan, rhamsan, zooghm, methyl an, chhin, cyclodextrin, chitosan, and mixtures thereof.
  • Suitable clays include, but are not limited to, smectites such as bentonite, kaolin, and laponite; magnesium tri silicate; magnesium aluminum silicate; and mixtures thereof.
  • suitable gelling starches include, but are not limited to, acid hydroly ed starches, swelling starches such as sodium starch glycolate and derivatives thereof and mixiures thereof.
  • suitable swelling cross-linked polymers include, but are not limited to, cross-linked polyvinyl pyrrolidone, cross-linked agar, and cross-linked carboxymethylcelluiose sodium, and mixtures thereof. j005
  • the carrier may contain one or more suitable excipients for the formulation of tablets.
  • excipients include, but are not limited to, fillers, adsorbents, binders, disintegrants, lubricants, giidants, release-modifying excipients, superdisintegrants, antioxidants, and mixtures thereof.
  • Suitable binders include, but are not limited to, dry binders such as polyvinyl pyrrolixione and hydroxypropyimethylcellulose; wet binders such as water-soluble polymers, including hydrocollolds such as acacia, alginates, agar, guar gum, locust bean, carrageenan, earboxymethylceilulose, tara, gum arable, tragacarsth, pectin, xanthan, gel!
  • dry binders such as polyvinyl pyrrolixione and hydroxypropyimethylcellulose
  • wet binders such as water-soluble polymers, including hydrocollolds such as acacia, alginates, agar, guar gum, locust bean, carrageenan, earboxymethylceilulose, tara, gum arable, tragacarsth, pectin, xanthan, gel!
  • Suitable disintegrates include, but are not limited to, sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked earboxymethylceilulose, starches, microcrystaliine cellulose, and mixtures thereof.
  • Suitable lubricants include, but are not limited to, long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glycerides waxes, and mixtures thereof.
  • Suitable glidants include, but are not limited to, colloidal silicon, dioxide.
  • Suitable release-modifying excipients include, but are not limited to, insoluble edible materials, pH-dependent polymers, and mixtures thereof.
  • Suitable insoluble edible materials for use as release-modifying excipients include, but are not limited to, water-insoluble polymers and low-melting hydrophobic materials, copolymers thereof, and mixtures thereof.
  • suitable water- insoluble polymers include, but are not limited to, ethyleellulose, polyvinyl alcohols, polyvinyl acetate, pol caprolactones, cellulose acetate and its derivatives, acrylates, methaerylates, acrylic acid copolymers, copolymers thereof and mixtures thereof.
  • Suitable low-melting hydrophobic materials include, but are not limited to, fats, fatty acid esters, phospholipids, waxes, and mixtures thereof
  • suitable fats include, but are not limited to, hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil, tree fatty acids and their salts, and mixtures thereof.
  • Suitable fatty acid esters include, but are not limited to, sucrose fatty acid esters, mono-, di-, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl iri!aurylate, glyceryl myri state, GiycoWax- 932, lauroyl macrogol ⁇ 32 glycerides, stearoyl maerogol-32 glycerides, and mixtures thereof.
  • Suitable phospholipids include phosphatidyl choline, phosphatidyl serene, phosphotidyl enositol, phospbotidic acid, and mixtures thereof.
  • suitable waxes include, but are not limited to, ca nauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystaUine wax, and paraffin wax; fat-containing mixtures such as chocolate, and mixtures thereof.
  • super disintegrates include, but are not limited to, crosearaieliose sodium, sodium starch glycolate and cross- linked povidone (crospovidone). In one embodiment the tablet core contains up to about 5 percent by weight of such super disintegrant.
  • antioxidants include, but are not limited to, tocopherols, ascorbic acid, sodium pyrosu!fite, buiylhydroxyto!uene, butylated hydroxy ant sole, edetie acid, and edetate salts, and mixtures thereof.
  • preservatives include, but are not limited to, citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, and sorbic acid, and mixtures thereof.
  • the immediate release coating has an average thickness of at least 50 microns, such as from about 50 microns to about 2500 microns; e.a., from about 250 microns to about 1000 microns.
  • the immediate release coating is typically compressed at a density of more than about 0.9 g ' ce, as measured by the weight and volume of that specific layer,
  • the immediate release coating contains a first portion and a second portion, wherein at least one of the portions contains the second pharmaceutically active agent.
  • the portions contact each other at a center axis of the tablet.
  • the first portion includes the first pharmaceutically active agent and the second portion includes the second pharmaceutically active agent.
  • the first portion contains the first pharmaceutically active agent and the second portion contains the second pharmaceutically active agent.
  • one of the portions contains a third pharmaceutically active agent.
  • one of the portions contains a second immediate release portion of the same pharmaceutically active agent as that contained in the tablet core,
  • the outer coating portion is prepared as a dry blend of materials prior to addition to the coated tablet core, in another embodiment the outer coating portion is included of a dried granulation including the pharmaceutically active agent f0063j Formulations with different drag release mechanisms described above could be combined in a final dosage form containing single or multiple units.
  • multiple units include multilayer tablets, capsules containing tablets, beads, or granules in a solid or liquid form, Typical, immediate release formulati ns include compressed tablets, gels, films, coatings, liquids and particles that can be encapsulated, for example, in a gelatin capsule. Many methods for preparing coatings, covering or incorporating drugs, are known in the art.
  • the immediate release dosage, unit of the dosage form i .e., a tablet, a pl urality of drug-containing beads, granules or particles, or an outer layer of a coated core dosage form, contains a therapeutically effective quantity of the active agent with conventional pharmaceutical excipients.
  • the immediate release dosage unit may or may not be coated, and may or may not be admixed with the delayed release dosage unit or units (as in an encapsulated mixture of immediate release drug-containing granules, particles or beads and delayed release drug-containing granules or beads).
  • Extended release formulations are generally prepared as diffusi n or osmotic systems, for example, as described in "Remington The Science and Practice of Pharmacy", 20th. Ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000).
  • a diffusion system typically consists of one of two types of devices, reservoir and matrix, which are wellknown and described in die art.
  • the matrix devices are generally prepared by compressing the daig with a slowly dissolving polymer carrier into a tablet form.
  • An immediate release portion can be added to tbe extended release system b means of either applying an immediate release layer on top of the extended release core; using coating or compression processes or in a multiple unit system such as a capsule containing extended and immediate release beads.
  • Delayed release dosage formulations are created by coating a solid dosage form with a film of a polymer which is insoluble in the acid environment of the stomach, but soluble in the neutral environment of small intestines.
  • the delayed release dosage units can be prepared, for example, by coating a drug or a drug-containing composition with a selected coating material.
  • the drug-containing composition may be a tablet for incorporation into a capsule, a tablet for use as an inner core in a "coated core" dosage form, or a plurality of drug-containing beads, particles or granules, for incorporation into either a tablet or capsule
  • a pulsed release dosage form is one that mimics a multiple dosing profile without repeated dosing and typically allows at least a twofold reduction in dosing frequency as compared to the drug presented as a conventional dosage form (e.g., as a solution or prompt dnig-rel easing, conventional solid dosage form).
  • a pulsed release profile is characterized by a time period of no release (lag time) or reduced release followed by rapid drug release.
  • Each dosage form contains a therapeutically effective amount of active agent.
  • approximately 30 wt % to 70 wt. %, preferably 40 wt % to 60 wt. %, of the total amount of active agent in the dosage form is released in the initial pulse, and, correspondingly approximately 70 wt. % to 3.0 wt %, preferably 60 wt, % to 40 wt. %, of the total amount of active agent in the dosage form is released in the second pulse.
  • the second pulse is preferably released approximately 3 hours to less than 14 hours, and more preferably approximately 5 hours to 12 hours, following administration.
  • Another dosage form contains a compressed tablet or a capsule having a drug- containing immediate release dosage unit, a delayed release dosage unit and an optional second delayed release dosage unit.
  • the immediate release dosage unit contains a plurality of beads, granules particles that release drug substantially immediately following oral administration to provide an initial dose.
  • the deiayed release dosage unit contains a plurality of coated beads or granules, which release drug approximately 3 hours to 14 hours following oral administration to provide a second dose.
  • dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1 % to 5% concentration), otherwise similar to the above parenteral solutions, may he prepared.
  • subject compositions of the present application maybe lyophilized or subjected to another appropriate drying technique such as spray drying.
  • the subject compositions may be administered once, or may be divided into a number of smaller doses to be administered at varying intervals of time, depending in part on the release rate of the compositions and the desired dosage.
  • Formulations useful in the methods provided herein include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of a subject composition which may be combined with a carrier material to produce a single dose may vary depending upon the subject being treated, and the particular mode of administration.
  • Methods of preparing these formulations or compositions include the step of bringing into association subject compositions with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a subject composition with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • the compounds of formula ⁇ described herein may be administered in inhalant or aerosol formulations.
  • the inhalant or aerosol formulations may comprise one or more agents, such as adjuvants, diagnostic agents, imaging agents, or therapeutic agents useful in inhalation therapy.
  • the final aerosol formulation ma for example contain 0.005-90% w/w, for instance 0.005-50%, 0.005-5% w/w. or 0.01-1.0% w/w, of medicament relative to the total weight of the formulation.
  • the subject composition is mixed with one or more pharmaceutically acceptable carriers and/or any of the following: (1 ) fillers or extenders, such as starches, lactose, sucrose., glucose, Stammiol, and/or silicic acid; (2) binders, such as, for example, carhoxymethylcelluiose, alginates, gelatin, polyvinyl pyrrotidone, sucrose and/or acacia; (3) hurnectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and g
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled geiatiti capsules using lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • Liquid dosage forms for oral administration include pharniaceuticaiiy acceptabie emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethy!
  • benzyl alcohol benzyl benzoate
  • propylene glycol 1,3-butylene glycol
  • oils in particular, cottonseed, corn, peanut, sunflower, soybean, olive, castor, and sesame oils
  • glycerol tet.rahydrofu.ryl alcohol
  • polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.
  • Suspensions in addition to the subject compositions, may contain suspending agents such as, for example, ethoxyiated isostearyl alcohols, polyoxyethy!ene sorbitol, and sorbitan esters, micr eiy stall in e cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, and mixtures thereof
  • suspending agents such as, for example, ethoxyiated isostearyl alcohols, polyoxyethy!ene sorbitol, and sorbitan esters, micr eiy stall in e cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, and mixtures thereof
  • Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared, by mixing a subject composition with one or more suitable non-irritating carriers comprising, for example, cocoa butter, polyethylene glycol, a suppositoiy wax, or a salicylate, and which is solid at room temperature, but liquid at. body temperature and, therefore, wilt melt, in the appropriate body cavity and release the encapsulated com ound(s) and com osition(s).
  • suitable non-irritating carriers comprising, for example, cocoa butter, polyethylene glycol, a suppositoiy wax, or a salicylate, and which is solid at room temperature, but liquid at. body temperature and, therefore, wilt melt, in the appropriate body cavity and release the encapsulated com ound(s) and com osition(s).
  • Formulations which are suitable for vaginal administration also include pessaries, tampons, creams,
  • Dosage forms for transdermal administration include powders, sprays, ointments, pastes, creams, lotions, geis, solutions, patches, and inhalants.
  • a subject composition may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propel lams that may be required.
  • the complexes may include lipophilic and hydrophilic groups to achieve the desired water solubility and transport properties.
  • the ointments, pastes, creams and gels may contain, in addition to subject compositions, other carriers, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacaiith, cellulose derivatives, polyethylene glycols, silicones, bentonit.es, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays may contain, in addition to a subject composition, excipienis such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamkie powder, or mixtures of such substances.
  • Sprays may additionally contain customary prope!lants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • a transdermal patch may comprise, a substrate sheet comprising a composite film formed of a resin composition comprising 100 parts by weight of a polyvinyl chloride-poiyurethane composite and 2-10 parts by weight of a st rene-ethylene-biuylene-styrene copolymer, a first adhesive layer on the one side of the composite film, and a polyalkyiene terephthalate film adhered to the one side of the composite film by means of the first adhesive layer, a primer layer which comprises a saturated polyester resin and is formed on the surface of the poiyaJkyiene terepli thai ate film; and a second adhesive layer comprising a siyrene-diene-styrene block copolymer containing a pharmaceutical agent layered on the primer layer.
  • a method for the manufacture of the above-mentioned substrate sheet comprises preparing the above resin composition molding the resin composition into a composite film by a calendar process, and then adhering a polyaikyiene terephthalate film on one side of the composite film by means of an adhesive layer thereb forming the substrate sheet, and forming a primer layer comprising a saturated polyester resin on the outer surface of the polyaikyiene terephthalate film
  • Another type of patch comprises incorporating the drug directly in a pharmaceutically acceptable adhesive and laminating the drug-containing adhesive onto a suitable backing member, e.g. a polyester backing membrane.
  • the drug should be present at a concentration which will not affect the adhesive properties, and at the same time deliver the required clinical dose.
  • Transdermal patches may be passive or active. Passive transdermal drug delivery systems currently available, such as the nicotine, estrogen and nitroglycerine patches, deliver small-molecule drugs. Many of the newly developed proteins and peptide drugs are too large to be delivered through passive transdermal patches and may be delivered using technology such as electrical assist (iontophoresis) for large-molecule drugs. 0087] Iontophoresis is a technique employed for enhancing the flux of ionized substances through membranes by application of electric current.
  • an iontophoretic membrane is given in U.S. Pat. No. 5,080,646 to Theeu es.
  • the principal mechanisms by which iontophoresis enhances molecular transport across the skin are (a) repelling a charged ion from an electrode of the same charge, (b) electroosmosis, the eonvective movement of solvent that occurs through a charged pore in response the preferential passage of counter -ions when an electric field is applied or (c) increase skin permeability due to application of electrical current,
  • kits it may be desirable to administer in the form of a kit, it may comprise a container for containing the separate compositions such as a divided bottle or a divided foil packet.
  • the kit comprises directions for the administration of the separate components.
  • the kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
  • Blister packs are well known in the packaging industry and are widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a plastic material that may be transparent.
  • Methods and compositions for the treatment of local pain comprising administering to a patient in need thereof a therapeutically effective amount of compound of Formula I:
  • a is independently 2,3 or 7;
  • each b is independently 3, 5 or 6;
  • e is i dependently 1 , 2 or 6;
  • e and d are each independently H, D, -Oil -OD, Ci-Cs-alkyi, -N3 ⁇ 4 or -COC3 ⁇ 4;
  • n is independently 1, 2, 3, 4 or 5.
  • the invention also includes methods for treating local pain including infiltration, nerve block, epidural, intrathecal anesthesia, pain, severe pain, chronic pain, chemotherapy induced pain, neuropathic paio, post herpetic neuralgia and neuralgia.
  • the crude reaction mass was dissolved in 250 ml of toluene, transferred to a separatory funnel, 250 ml of water was added and basified with 50 mi of 20% aqueous sodium hydroxide. The organic layer was separated and the aqueous layer was extracted twice with 100 ml of toluene. The combined organic layer after extraction was dried over MgSO and concentrated in a rotary evaporator. The crude solid mass obtained was recr stall i zed from 70 ml of toluene to provide 18.5 g of slightl y pink solid of compound 4 in 72 % yield, M P. 1 16
  • Bupivacaine (3mg mL) was prepared in 0. %(w/v) sodium chloride.
  • the chromatographic system consisted of a F -80 chromatographic pump (BAS, West Lafayette, IN, USA), an off-line injector (CMA/I 0, Sweden) equipped with a 20L sample loop injector (Rheodynemodel 7125) and a UV-Vis detector (Soma, Tokyo, Japan) that operated at room temperature (25 ⁇ 2 » C). Separation was achieved on a LiChrosphere60RP- select B column (4.6mm ' 250mm, 5m, Merck).
  • the mobile phase for plasma, brain homogenate, blood dialysate and brain diaiysate was comprised oil OmM potassium dihydrogenphosphal -acetoni tri le-tri ethyl ami ne (67:33:0.01 ), adjusted to pH4.3 with H3 P04.
  • the mobile phase for bile dialysate consisted of lOmM potassium dihydrogen phosphate-acetoaitriie-triethylaiiiine (60:40:0,01 ), adjusted to ⁇ . ⁇ with 3 ⁇ 4PQ 4 .
  • the flow rate was set atl .OmL/min for both mobile phases.
  • sample refers to a sample of a body fluid, to a sample of separated cells or to a sample from a tissue or an organ.
  • Samples of body fluids can be obtained by well known techniques and include, preferably, samples of blood, plasma, serum, or urine, more preferably, samples of blood, plasma or serum.
  • Tissue or organ samples may be obtained from any tissue or organ by, e.g., biopsy.
  • Separated cells may be obtained from the body fluids or the tissues or organs by separating techniques such as centrifugation or cell sorting
  • cell-, tissue- or organ samples are obtained from those cells, tissues or organs which express or produce the peptides referred to herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne des composés de formule I ou leurs sels pharmaceutiquement acceptables, ainsi que leurs formes polymorphes, leurs solvates, leurs énantiomères, leurs stéréoisomères et leurs hydrates. Elle concerne des compositions pharmaceutiques comprenant une quantité efficace de composés de formule I; et des méthodes de traitement de la douleur locale. Ces compositions peuvent être formulées pour administration par voie orale, buccale, rectale, topique, transdermique, transmuqueuse, intraveineuse, parentérale, sous forme de sirop ou d'injection. Ces compositions peuvent être utilisées pour traitement par anesthésie par infiltration, anesthésie tronculaire, anesthésie péridurale ou anesthésie intrathécale. Elles peuvent être utilisées pour traiter la douleur, la douleur sévère, la douleur chronique, la douleur induite par la chimiothérapie, la douleur neuropathique, la névralgie post-herpétique, la névralgie, la maladie des motoneurones, la neuropathie diabétique, les lésions, la douleur postopératoire, l'arthrose, la polyarthrite rhumatoïde, la sclérose en plaques, les lésions de la moelle épinière, la migraine, la douleur neuropathique liée au VIH, la douleur cancéreuse, et la douleur du bas du dos.
PCT/IB2013/051268 2012-05-10 2013-02-16 Compositions et méthodes de traitement de la douleur locale WO2013168006A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP13788349.2A EP2882745A2 (fr) 2012-05-10 2013-02-16 Compositions et méthodes de traitement de la douleur locale
CA2873138A CA2873138A1 (fr) 2012-05-10 2013-02-16 Compositions et methodes de traitement de la douleur locale
SG11201407323WA SG11201407323WA (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain
AU2013257727A AU2013257727B2 (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain
CN201380030659.5A CN105612155A (zh) 2012-05-10 2013-02-16 治疗局部疼痛的组合物和方法
JP2015510898A JP2016508956A (ja) 2012-05-10 2013-02-16 局所疼痛の治療のための組成物と治療法
ZA2014/08055A ZA201408055B (en) 2012-05-10 2014-11-04 Compositions and methods for the treatment of local pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1843CH2012 2012-05-10
IN1843/CHE/2012 2012-05-10

Publications (2)

Publication Number Publication Date
WO2013168006A2 true WO2013168006A2 (fr) 2013-11-14
WO2013168006A3 WO2013168006A3 (fr) 2016-09-01

Family

ID=54193695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/051268 WO2013168006A2 (fr) 2012-05-10 2013-02-16 Compositions et méthodes de traitement de la douleur locale

Country Status (8)

Country Link
EP (1) EP2882745A2 (fr)
JP (1) JP2016508956A (fr)
CN (1) CN105612155A (fr)
AU (1) AU2013257727B2 (fr)
CA (1) CA2873138A1 (fr)
SG (1) SG11201407323WA (fr)
WO (1) WO2013168006A2 (fr)
ZA (1) ZA201408055B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US10111704B2 (en) 2002-09-30 2018-10-30 Relievant Medsystems, Inc. Intraosseous nerve treatment
US10357258B2 (en) 2012-11-05 2019-07-23 Relievant Medsystems, Inc. Systems and methods for creating curved paths through bone
IL267649A (en) * 2016-12-26 2019-08-29 Kandula Mahesh Compounds and methods for the treatment of chronic pain
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
US11007010B2 (en) 2019-09-12 2021-05-18 Relevant Medsysterns, Inc. Curved bone access systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302218D0 (sv) * 1993-06-28 1993-06-28 Ab Astra New use
CN1187813A (zh) * 1995-05-01 1998-07-15 斯科舍集团有限公司 作为生物活性化合物的脂肪酸酯
GB9704349D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
CA2308495C (fr) * 1997-11-19 2009-01-06 Darwin Discovery Limited Formulation anesthesique
US7560442B2 (en) * 2001-04-30 2009-07-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Pharmaceutically active uridine esters
WO2009061497A1 (fr) * 2007-11-07 2009-05-14 Svip5 Llc Libération lente de sels organiques d'anesthésique local pour un soulagement de la douleur
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US20120022147A1 (en) * 2011-08-17 2012-01-26 Krisani Biosciences (P) Ltd 2, 6 xylidine derivatives for the treatment of pain

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111704B2 (en) 2002-09-30 2018-10-30 Relievant Medsystems, Inc. Intraosseous nerve treatment
US10478246B2 (en) 2002-09-30 2019-11-19 Relievant Medsystems, Inc. Ablation of tissue within vertebral body involving internal cooling
US11596468B2 (en) 2002-09-30 2023-03-07 Relievant Medsystems, Inc. Intraosseous nerve treatment
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
US11737814B2 (en) 2012-09-12 2023-08-29 Relievant Medsystems, Inc. Cryotherapy treatment for back pain
US11701168B2 (en) 2012-09-12 2023-07-18 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
US11690667B2 (en) 2012-09-12 2023-07-04 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
US11234764B1 (en) 2012-11-05 2022-02-01 Relievant Medsystems, Inc. Systems for navigation and treatment within a vertebral body
US10517611B2 (en) 2012-11-05 2019-12-31 Relievant Medsystems, Inc. Systems for navigation and treatment within a vertebral body
US11974759B2 (en) 2012-11-05 2024-05-07 Relievant Medsystems, Inc. Methods of navigation and treatment within a vertebral body
US10357258B2 (en) 2012-11-05 2019-07-23 Relievant Medsystems, Inc. Systems and methods for creating curved paths through bone
US11160563B2 (en) 2012-11-05 2021-11-02 Relievant Medsystems, Inc. Systems for navigation and treatment within a vertebral body
US11291502B2 (en) 2012-11-05 2022-04-05 Relievant Medsystems, Inc. Methods of navigation and treatment within a vertebral body
US11065046B2 (en) 2013-08-08 2021-07-20 Relievant Medsystems, Inc. Modulating nerves within bone
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US10456187B2 (en) 2013-08-08 2019-10-29 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
IL267649A (en) * 2016-12-26 2019-08-29 Kandula Mahesh Compounds and methods for the treatment of chronic pain
EP3558279A4 (fr) * 2016-12-26 2020-12-02 Cellix Bio Private Limited Compositions et méthode s pour le traitement d'une douleur chronique
US11207100B2 (en) 2019-09-12 2021-12-28 Relievant Medsystems, Inc. Methods of detecting and treating back pain
US11426199B2 (en) 2019-09-12 2022-08-30 Relievant Medsystems, Inc. Methods of treating a vertebral body
US11202655B2 (en) 2019-09-12 2021-12-21 Relievant Medsystems, Inc. Accessing and treating tissue within a vertebral body
US11123103B2 (en) 2019-09-12 2021-09-21 Relievant Medsystems, Inc. Introducer systems for bone access
US11007010B2 (en) 2019-09-12 2021-05-18 Relevant Medsysterns, Inc. Curved bone access systems

Also Published As

Publication number Publication date
CA2873138A1 (fr) 2013-11-14
SG11201407323WA (en) 2014-12-30
CN105612155A (zh) 2016-05-25
JP2016508956A (ja) 2016-03-24
WO2013168006A3 (fr) 2016-09-01
ZA201408055B (en) 2016-03-30
EP2882745A2 (fr) 2015-06-17
AU2013257727A1 (en) 2014-11-27
AU2013257727B2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
WO2013167993A1 (fr) Compositions et méthodes de traitement de troubles neurologiques dégénératifs
WO2013167996A1 (fr) Compositions et méthodes de traitement du syndrome métabolique
WO2013167988A1 (fr) Compositions et méthodes de traitement de la toux
US9492409B2 (en) Compositions and methods for the treatment of local pain
WO2013168006A2 (fr) Compositions et méthodes de traitement de la douleur locale
US9108942B1 (en) Compositions and methods for the treatment of moderate to severe pain
US9273061B2 (en) Compositions and methods for the treatment of chronic pain
WO2015033279A1 (fr) Compositions et méthodes pour le traitement de l'homocystinurie
WO2014006529A2 (fr) Compositions et méthodes de traitement de la douleur modérée à aiguë
WO2013168008A1 (fr) Compositions et méthodes de traitement d'affections neurologiques
US9346742B2 (en) Compositions and methods for the treatment of fibromyalgia pain
WO2014057439A2 (fr) Compositions et procédés de traitement de maladies neurologiques et des complications associées
WO2014068461A2 (fr) Compositions et méthodes de traitement d'une inflammation aiguë
WO2013168016A1 (fr) Compositions et méthodes de traitement du syndrome métabolique
US9242939B2 (en) Compositions and methods for the treatment of respiratory disorders
US9173877B1 (en) Compositions and methods for the treatment of local pain
WO2013168010A1 (fr) Compositions et méthodes de traitement de la douleur sévère
WO2013168025A1 (fr) Compositions et méthodes de traitement des maladies de coagulation du sang
WO2014037833A2 (fr) Compositions et méthodes de traitement d'une inflammation et de troubles lipidiques
WO2015028956A1 (fr) Compositions et méthodes de traitement de troubles de l'oxydation des acides gras
WO2014006528A2 (fr) Compositions et méthodes de traitement de troubles neurologiques dégénératifs
US9394288B2 (en) Compositions and methods for the treatment of asthma and allergy
WO2014118649A2 (fr) Compositions et méthodes pour le traitement de maladies cardiovasculaires
WO2013168001A1 (fr) Compositions et méthodes de traitement de la douleur modérée à sévère
WO2014195849A2 (fr) Composition et méthodes de traitement de maladies cérébrovasculaires

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref document number: 2873138

Country of ref document: CA

Ref document number: 2015510898

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013788349

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2013257727

Country of ref document: AU

Date of ref document: 20130216

Kind code of ref document: A